Literature DB >> 9357397

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine.

S G Gourlay1, N L Benowitz.   

Abstract

BACKGROUND AND OBJECTIVES: Delivery of a high concentration bolus of nicotine through the arterial circulation is believed to be an important determinant of the addictive, behavioral, and physiologic effects of nicotine. To better understand the pharmacologic features of nicotine with different routes of administration, we measured arterial and venous plasma concentrations of nicotine, cotinine, epinephrine, and norepinephrine after tobacco smoking, intravenous nicotine infusion, and use of a nicotine nasal spray. SUBJECTS AND METHODS: Arterial and venous blood samples were drawn simultaneously from 12 male smokers. Six subjects received a single dose of 1 mg nicotine nasal spray, and six subjects smoked cigarettes, one puff per minute for 10 minutes. All 12 subjects were administered nicotine as a 30-minute infusion beginning 70 minutes after administration of the nicotine nasal spray or commencement of smoking.
RESULTS: The mean peak arterial plasma concentrations of nicotine (Cmax) after smoking or administration of nicotine nasal spray, or intravenous nicotine averaged twofold those of venous plasma. For nicotine nasal spray, the time to Cmax was much faster for arterial than for venous plasma (median, 5 versus 18 minutes, p < 0.01). Intravenous nicotine produced the greatest increase in plasma epinephrine concentration, although smoking had a greater chronotropic effect. Acute tolerance to the chronotropic effects of nicotine was suggested at pharmacodynamic analysis with venous nicotine concentrations, whereas analysis of arterial concentrations found the opposite--a time lag between plasma concentration and effect.
CONCLUSION: Nicotine is rapidly absorbed from nicotine nasal spray. The Cmax of nicotine after smoking or administration of nicotine nasal spray, or intravenous nicotine is substantially higher in arterial than venous plasma. Acute tolerance to the chronotropic effects of nicotine is not apparent if arterial plasma concentrations are measured.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357397     DOI: 10.1016/S0009-9236(97)90124-7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  62 in total

Review 1.  Vaccines against nicotine: how effective are they likely to be in preventing smoking?

Authors:  F J Vocci; C N Chiang
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

3.  Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum.

Authors:  Maria Pitsiu; Jean-Michel Gries; Neal Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

4.  Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations.

Authors:  Mark G LeSage; Daniel E Keyler; Greg Collins; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

5.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

6.  Crotonaldehyde-induced vascular relaxation and toxicity: Role of endothelium and transient receptor potential ankyrin-1 (TRPA1).

Authors:  L Jin; G Jagatheesan; J Lynch; L Guo; D J Conklin
Journal:  Toxicol Appl Pharmacol       Date:  2020-04-19       Impact factor: 4.219

Review 7.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Effects of preoperative smoking cessation on the incidence and risk of intraoperative and postoperative complications in adult smokers: a systematic review.

Authors:  Alice Theadom; Mark Cropley
Journal:  Tob Control       Date:  2006-10       Impact factor: 7.552

Review 9.  Constitutional mechanisms of vulnerability and resilience to nicotine dependence.

Authors:  N Hiroi; D Scott
Journal:  Mol Psychiatry       Date:  2009-02-24       Impact factor: 15.992

Review 10.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.